FDA Panel Oks Tegaserod for IBS-C in Women with Low CV Risk FDA Panel Oks Tegaserod for IBS-C in Women with Low CV Risk
The Gastrointestinal Drugs Advisory Committee of the FDA recommended reintroducing tegaserod maleate for women with irritable bowel syndrome and low cardiovascular risk.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news
More News: Cardiology | Cardiovascular | Gastroenterology | Health | Heart | Irritable Bowel Syndrome | Women